Allarity Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
ALLR$0.94-2.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
As of December 31, 2023 and 2022
(U.S. dollars in thousands, except for share and per share data*)
| December 31, | December 31, | |
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets: | ||
| Cash | $166 | $2,029 |
| Other current assets | 209 | 1,559 |
| Prepaid expenses | 781 | 591 |
| Tax credit receivable | 815 | 789 |
| Total current assets | 1,971 | 4,968 |
| Non-current assets: | ||
| Property, plant and equipment, net | 20 | 21 |
| Operating lease right of use assets | — | 6 |
| Intangible assets | 9,871 | 9,549 |
| Total assets | $11,862 | $14,544 |
| LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $8,416 | $6,251 |
| Accrued liabilities | 1,309 | 1,904 |
| Warrant derivative liability | 3,083 | 374 |
| Income taxes payable | 59 | 41 |
| Convertible promissory note and accrued interest, net of debt discount | 1,300 | — |
| Secured promissory notes | — | 2,644 |
| Operating lease liabilities, current | — | 8 |
| Total current liabilities | 14,167 | 11,222 |
| Non-current liabilities: | ||
| Convertible promissory note and accrued interest, net of debt discount | — | 1,083 |
| Deferred tax | 446 | 349 |
| Total liabilities | 14,613 | 12,654 |
| Commitments and contingencies (Note 17) | ||
| Redeemable preferred stock (500,000 shares authorized) | ||
| Series A Preferred Stock $0.0001 par value (20,000 shares designated) shares issued and outstanding at December 31, 2023 and 2022, were 1,417 and 13,586, respectively (liquidation preference of $17.54 at December 31, 2023) | — | 2,001 |
| Series B Preferred Stock $0.0001 par value (200,000 shares designated); shares issued at December 31, 2023 and 2022, were 0 and 190,786, respectively (liquidation preference of $0 at December 31, 2023) | — | 2 |
| Series C Convertible Preferred stock $0.0001 par value (50,000 and 0 shares designated at December 31, 2023 and 2022, respectively); shares issued and outstanding at December 31, 2023 were 0 | — | — |
| Total redeemable preferred stock | — | 2,003 |
| Stockholders’ (deficit) equity | ||
| Series A Preferred stock $0.0001 par value (20,000 shares designated) shares issued and outstanding at December 31, 2023 and 2022, were 1,417 and 13,586, respectively (liquidation preference of $17.54 at December 31, 2023) | 1,742 | — |
| Common Stock, $0.0001 par value (750,000,000 and 30,000,000 shares authorized, at December 31, 2023 and 2022, respectively); shares issued and outstanding at December 31, 2023 and 2022, were 5,886,934 and 11,356, respectively | — | — |
| Additional paid-in capital | 90,369 | 83,158 |
| Accumulated other comprehensive loss | (411) | (721) |
| Accumulated deficit | (94,451) | (82,550) |
| Total stockholders’ deficit | (2,751) | (113) |
| Total liabilities, preferred stock and stockholders’ (deficit) equity | $11,862 | $14,544 |
| * | All common share data has been retroactively adjusted to effect reverse stock splits in 2023 (see Notes 1 and 10.) |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.